Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of the anti-hepcidin Spiegelmer NOX-H94 on
iron homeostasis during systemic inflammation induced by endotoxin.
In the human endotoxemia model, intravenously administered lipopolysaccharide elicits an
inflammatory response with release of pro-inflammatory cytokines, such as IL-6 and TNF-alfa,
with subsequent induction of hepcidin. As a consequence of hepcidin induction, serum iron
concentrations decrease.
This study in healthy subjects investigates the capacity of NOX-H94 to inactivate hepcidin
and to prevent serum iron decrease in a pathophysiological model prior to studying the
efficacy of NOX-H94 in patients with anemia of chronic disease.